Isomorphic Labs, the Alphabet/Google-backed AI drug discovery firm, closed a $2.1 billion Series B round to scale its drug design platform and accelerate internal pipeline candidates toward clinical development. Thrive Capital led the raise, joined by Alphabet and Google’s GV, with additional backers including Temasek, CapitalG, and a UK government AI fund. The company said the financing will be used to develop and deploy its IsoDDE engine and expand the number of programs supported by its unified model stack, which has previously fueled partner collaborations with large pharma. The round arrives as investors refocus on measurable clinical pathways for AI-enabled therapeutics.